Nepidermin
Nepidermin, also known as recombinant human epidermal growth factor, is a recombinant form of human epidermal growth factor and a cicatrizant. It was developed by Daewoong Pharmaceutical. As a recombinant form of EGF, nepidermin is an agonist of the epidermal growth factor receptor, and is the first EGFR agonist to be marketed.
It is marketed as an ointment for the treatment of diabetic foot ulcers, wounds, and alopecia in Vietnam, the Philippines, Thailand, and China.
As of 2017 it was in clinical trials in South Korea for the treatment of stomatitis and for reversal of skin side effects caused by erlotinib.
